<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7297930\results\search\drug\results.xml">
  <result pre="process called â€œrepurposingâ€� or â€œrepositioningâ€� [2]. Notably, in case reports," exact="hydroxychloroquine" post="(HCQ) has been regarded as an effective regimen reducing"/>
  <result pre="doses of the drug might be administered without documented cardiotoxicities." exact="Atazanavir" post="Mechanisms Using a deep learning-based drug-target interaction model called"/>
  <result pre="cleaving into the working form. In recent in vitro experiments," exact="atazanavir" post="inhibited SARS-CoV-2 replication and pro-inflammatory cytokines [14]. Clinical trials"/>
  <result pre="of CYP3A4 and UGT1A1 and a strong inhibitor of OATP1B1," exact="atazanavir" post="may increase the plasma concentrations of other drugs such"/>
  <result pre="as proton-pump inhibitors, antacids, and H2-receptor antagonists. Statins such as" exact="simvastatin" post="and atorvastatin are also known as CYP3A4 isoenzyme substrates"/>
  <result pre="inhibitors, antacids, and H2-receptor antagonists. Statins such as simvastatin and" exact="atorvastatin" post="are also known as CYP3A4 isoenzyme substrates [16]. Cardiovascular"/>
  <result pre="Cardiovascular Risks Dose-related asymptomatic prolongation in the PR interval with" exact="atazanavir" post="has been observed in clinical studies [17, 18]. It"/>
  <result pre="require dose reductions or avoidance of CYP3A-mediated drugs such as" exact="rivaroxaban" post="and apixaban. Ritonavir/lopinavir can also influence the activity of"/>
  <result pre="results in decreased serum concentrations of the active metabolites of" exact="clopidogrel" post="and prasugrel and increased serum concentrations of ticagrelor. The"/>
  <result pre="CYP450-based interaction with lopinavir/ritonavir is expected. Otherwise, atorvastatin, pravastatin, and" exact="pitavastatin" post="can also be considered at a low starting dose."/>
  <result pre="(THDMS-COVID-19) combining various regimens including protease inhibitors, oseltamivir, favipiravir, and" exact="hydroxychloroquine" post="was initiated to test whether the cocktail formula is"/>
  <result pre="prolongation risk of favipiravir is considered to be low [36]." exact="Ribavirin" post="Mechanisms Similar to remdesivir, ribavirin functions as an RNA-dependent"/>
  <result pre="considered to be low [36]. Ribavirin Mechanisms Similar to remdesivir," exact="ribavirin" post="functions as an RNA-dependent RNA polymerase inhibitor and is"/>
  <result pre="approved for the treatment of RSV and HCV [37]. Although" exact="ribavirin" post="was recommended for COVID-19 treatment according to Chinese guidelines,"/>
  <result pre="to evaluate the therapeutic effects on COVID-19 [25]. Drug Interactions" exact="Ribavirin" post="is metabolized by a reversible phosphorylation pathway or a"/>
  <result pre="potential for P450 enzyme-based interactions. However, case reports showed that" exact="ribavirin" post="has variable effects on warfarin dosing [40]. The detailed"/>
  <result pre="However, case reports showed that ribavirin has variable effects on" exact="warfarin" post="dosing [40]. The detailed mechanism has yet to be"/>
  <result pre="ascariasis, and lymphatic filariasis [42, 43]. Beyond its anti-parasite effects," exact="ivermectin" post="has also been identified as an inhibitor of interactions"/>
  <result pre="response [45]. An in vitro study showed that a single" exact="ivermectin" post="treatment reduced SARS-CoV-2 by 5000-fold at 48Â h in"/>
  <result pre="have been documented in case reports [47, 48]. Immune-Modulating Drugs" exact="Hydroxychloroquine" post="(HCQ; Plaquenil) Mechanisms Hydroxychloroquine has actions, pharmacokinetics, and metabolism"/>
  <result pre="case reports [47, 48]. Immune-Modulating Drugs Hydroxychloroquine (HCQ; Plaquenil) Mechanisms" exact="Hydroxychloroquine" post="has actions, pharmacokinetics, and metabolism similar to those of"/>
  <result pre="Hydroxychloroquine has actions, pharmacokinetics, and metabolism similar to those of" exact="chloroquine" post="[49]. As an anti-malarial and anti-autoimmune agent, by sequestering"/>
  <result pre="France demonstrated a positive effect of HCQ in combination with" exact="azithromycin" post="[5]. Upon this finding, although the US FDA issued"/>
  <result pre="although the US FDA issued an Emergency Use Authorization for" exact="hydroxychloroquine" post="in treating COVID-19, the trial design has been questioned."/>
  <result pre="toxicities including cardiomyopathy and fatal arrhythmia [7, 8]. Drug Interactions" exact="Chloroquine" post="and HCQ undergo CYP-mediated metabolism by CYPs 2C8, 3A4,"/>
  <result pre="as azithromycin, metabolic derangements, and renal failure [55]. Of note," exact="hydroxychloroquine" post="has a long half-life of 40Â days [56]. ECG"/>
  <result pre="published study of 15 patients with COVID-19, tocilizumab combined with" exact="methylprednisolone" post="ameliorated increased CRP and IL-6, but the result was"/>
  <result pre="multiple sclerosis [76]. By structurally resembling the lipid sphingosine-1-phosphate (S1P)," exact="fingolimod" post="can act as a highly potent functional antagonist of"/>
  <result pre="T cells [76]. Similar to the immunomodulatory properties of IFN-I," exact="fingolimod" post="is regarded as a method of treating the SARS-CoV-2"/>
  <result pre="and open-label study is preparing to evaluate the efficacy of" exact="fingolimod" post="for treating COVID-19 [78]. Drug Interactions Fingolimod is primarily"/>
  <result pre="by CYP4F2 [79]. Since few drugs are metabolized by CYP4F2," exact="fingolimod" post="is expected to have a relatively low potential for"/>
  <result pre="and beta-blockers [80]. CYP4F2 genotypes were observed contributing to both" exact="warfarin" post="clearance and sensitivity differences [79]. Cardiovascular Risks Given that"/>
  <result pre="retinal vein occlusion [76, 81]. Conversely, upon its atheroprotective effects," exact="fingolimod" post="diminishes atherosclerosis plaque volume and macrophage and collagen content"/>
  <result pre="kinase (Pak1), a pivotal regulator of channel activity and contractility," exact="fingolimod" post="resists load stress-induced murine hypertrophic remodeling without deterioration of"/>
  <result pre="Anti-viral drugs Â Â Remdesivir A nucleotide prodrug, transforming to" exact="adenosine" post="analogue, causing RNA pre-mature termination and inhibiting viral replication"/>
  <result pre="reported Liver toxicity (rare) 14, 15, 17, 73 Â Â" exact="Atazanavir" post="An analog of the peptide chain substrate binding to"/>
  <result pre="into the working form. Binding to SARS-CoV-2 3C-like proteinase (3CLpro);" exact="Atazanavir" post="inhibits SARS-CoV-2 replication and pro-inflammatory cytokine in vitro experiments"/>
  <result pre="2nd or 3rd degree AVB; lopinavir/ritonavir; decreased serum concentrations of" exact="clopidogrel" post="and prasugrel but increase statins, ticagrelor, rivaroxaban, and apixaban"/>
  <result pre="of clopidogrel and prasugrel but increase statins, ticagrelor, rivaroxaban, and" exact="apixaban" post="Liver toxicity, pancreatitis, GI upset, neurotoxicity 22, 26, 28,"/>
  <result pre="Minimal clinically significant drug interactions Not reported 34â€&quot;38 Â Â" exact="Ribavirin" post="A nucleoside inhibitor, stopping viral RNA synthesis and mRNA"/>
  <result pre="No report of cytochrome P450 enzyme mediated metabolism of ribavirin." exact="Ribavirin" post="has no characterized direct CV toxicity; ribavirin has variable"/>
  <result pre="metabolism of ribavirin. Ribavirin has no characterized direct CV toxicity;" exact="ribavirin" post="has variable effects on warfarin dosing Liver toxicity, hematologic"/>
  <result pre="no characterized direct CV toxicity; ribavirin has variable effects on" exact="warfarin" post="dosing Liver toxicity, hematologic disorder 40, 43, 44 Â"/>
  <result pre="the lymph node T cells As an effective immunology modulator," exact="fingolimod" post="with potentials of anti-SARS-CoV-2 Multiple sclerosis, refractory NCT04280588 Metabolism"/>
  <result pre="Parola P, Hoang VT, Meddeb L, Mailhe M, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
  <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="Parola P, Meddeb L, Mailhe M, Doudier B, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
  <result pre="Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75:2352â€&quot;71. 7.ChenC-YWangF-LLinC-CChronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin"/>
  <result pre="SM, et al. A prospective evaluation of the effect of" exact="atazanavir" post="on the QTc interval and QTc dispersion in HIV-positive"/>
  <result pre="ME. Prolonged QT interval and torsades de pointes associated with" exact="atazanavir" post="therapy. Clin Infect Dis. 2007;44(6):e67â€&quot;8. 20.FengH-PCaroLFandozziCChuXGuoZTalatyJet al.Pharmacokinetic interactions between"/>
  <result pre="al.Pharmacokinetic interactions between the hepatitis C virus inhibitors elbasvir and" exact="grazoprevir" post="and HIV protease inhibitors ritonavir, atazanavir, lopinavir, and darunavir"/>
  <result pre="Zhu WY, Wang Y, Wang GQ. A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-a possible reference"/>
  <result pre="hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787â€&quot;99. 25.Lopinavir/Ritonavir," exact="Ribavirin" post="and IFN-beta Combination for nCoV Treatment. 2020;NCT04276688. 26.van der"/>
  <result pre="(COVID-19). 2020;ChiCTR2000029600. 34.Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and" exact="Hydroxychloroquine" post="for Treatment of COVID-19 : A Randomized Control Trial"/>
  <result pre="MG, Liang TJ. The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis C. Antivir Chem Chemother. 2012;23(1):1â€&quot;12."/>
  <result pre="forms: ribavirin. J Pharm Sci. 2016;105(4):1362â€&quot;9. 40.Schulman S. Inhibition of" exact="warfarin" post="activity by ribavirin. Ann Pharmacother. 2002;36(1):72â€&quot;4. 41.Atif M, Estrada-Mondragon"/>
  <result pre="Nguyen B, Lynch JW, Keramidas A. Effects of glutamate and" exact="ivermectin" post="on single glutamate-gated chloride channels of the parasitic nematode"/>
  <result pre="Diau J, Asugeni R, MacLaren D, et al. Impact of" exact="ivermectin" post="administered for scabies treatment on the prevalence of head"/>
  <result pre="DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined" exact="ivermectin" post="and albendazole for treatment of intestinal helminth and Wuchereria"/>
  <result pre="JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antivir Res."/>
  <result pre="Neca J, Soucek P, Havlasova J, et al. Effect of" exact="ivermectin" post="on activities of cytochrome P450 isoenzymes in mouflon (Ovis"/>
  <result pre="Loustaud-Ratti V, Vidal E, Bedane C. Systemic adverse reactions with" exact="ivermectin" post="treatment of scabies. Ann Dermatol Venereol. 2006;133(10):784â€&quot;7. 48.Goa KL,"/>
  <result pre="49.Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L." exact="Chloroquine" post="and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911."/>
  <result pre="Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and" exact="hydroxychloroquine" post="for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911. 50.Schrezenmeier E,"/>
  <result pre="Oncol. 2014;1(1):e29911. 50.Schrezenmeier E, Dorner T. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155â€&quot;66."/>
  <result pre="Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
  <result pre="Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int J Antimicrob Agents. 2020;105945:105945. 54.Colson P,"/>
  <result pre="54.Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D." exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19. Int"/>
  <result pre="Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
  <result pre="Kalla M, Yavari A, Mirams GR, Douglas G, et al." exact="Hydroxychloroquine" post="reduces heart rate by modulating the hyperpolarization-activated current If:"/>
  <result pre="56.Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771â€&quot;9."/>
  <result pre="X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and" exact="simvastatin" post="in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735â€&quot;40."/>
  <result pre="novel, first oral therapy for multiple sclerosis: the development of" exact="fingolimod" post="(FTY720, Gilenya)Discov Med2011126421322821955849 77.Rosa SGV, Santos WC. Clinical trials"/>
  <result pre="R, Ferratini M, Toccafondi A, et al. 6-Month effects of" exact="fingolimod" post="on indexes of cardiovascular autonomic control in multiple sclerosis."/>
 </snippets>
</snippetsTree>
